Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2023 13:00 ET | Source: Flag Therapeutics, Inc.

FLAG Therapeutics Receives Rare Pediatric Disease (RPD) Designation for FLAG-003 for the Treatment of Children with Diffuse Intrinsic Pontine Glioma (DIPG)

RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine...
November 21, 2022 09:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results

R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
September 28, 2022 08:55 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting

AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
September 14, 2022 08:15 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
May 03, 2022 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer

AGOURA HILLS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company” or “We”) (OTCQB:OTLC), today announced the appointment of Dr. Fatih Uckun as its...
April 07, 2022 10:00 ET | Source: Oncotelic Therapeutics, Inc.

Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), issued the following shareholder letter today. Dear Fellow...
April 04, 2022 07:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction

AGOURA HILLS, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the formation of a Joint Venture (“JV”) with Dragon...
March 03, 2022 08:01 ET | Source: Oncotelic Therapeutics, Inc.

Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief...
February 03, 2015 08:10 ET | Source: Mazor Robotics

Mazor Robotics Announces Major Milestone in Improving the Management of Lethal Brain Cancer in Children

ORLANDO, FLA., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Mazor Robotics (www.mazorrobotics.com), a global leader in the development and distribution of innovative surgical guidance systems for spine and brain...